Investment analysts at StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James cut shares of Jounce Therapeutics from an “outperform” rating to a “market […]
StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the stock. A number of other analysts have also issued reports on JNCE. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in […]
StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report released on Monday morning. The brokerage issued a hold rating on the stock. Several other research firms have also issued reports on JNCE. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in a report […]
StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the stock. A number of other analysts have also weighed in on the stock. Sumitomo Mitsui Financial Group restated a neutral rating on shares of Jounce […]
Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) has received a consensus rating of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokers that […]